About
About Shionogi
Our leadership team
History and values
Global affiliates and locations
Investor relations
Sustainability
Sustainability
Tax strategy
Transparency
Governance, policies and position statements
Carbon reduction plan
Innovation
Innovation
Our areas of focus
Strategic partnering in Europe
Global innovation
Grants and donations
News
Investors
Careers
Contact
Europe
Worldwide
Home
News
Press Releases
Naldemedine meets primary endpoint in Phase 3 study for the treatment of opioid-induced constipation
Release
2015/08/03
Naldemedine meets primary endpoint in Phase 3 study for the treatment of opioid-induced constipation
